Nevro Launches HFX AdaptivAI for Spinal Cord Stimulation

Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, has announced the U.S. Food and Drug Administration approval and limited market release of its HFX iQ with HFX AdaptivAI – a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.
 
HFX AdaptivAI technology builds on clinical research and big data and is the only technology with artificial intelligence (AI) to provide patients suffering from chronic pain with an unprecedented level of personalized, responsive pain relief.
 
“Nevro is further establishing its position as the leading developer of data-driven solutions for pain management through the launch of HFX iQ with HFX AdaptivAI,” said Kevin Thornal, Nevro’s CEO and president. “HFX AdaptivAI delivers personalized pain relief, utilizing AI and leveraging millions of data points and ten years of innovation and patient care. We believe this new solution is a major milestone, and it demonstrates our dedication to freeing patients from the burden of chronic pain through evidence-based therapies that transform patients’ lives. Importantly, HFX AdaptivAI puts patients in control of their pain relief while, at the same time, providing physicians the ability to monitor their patient’s pain journey – closing the loop that matters.”
 
HFX AdaptivAI is engineered to maximize pain relief over time by continuing to optimize therapy even when pain relief over 50% has been achieved¹. It uses Bipole Interlacing, a proprietary technology that creates customized therapy programs in real-time using direct patient input¹**. Through therapy optimization, advanced Smart Power technology allows patients to charge their device as little as six times per year².
 
HFX AdaptivAI technology gathers real-time quality of life (QoL) metrics and device data, enabling more impactful patient-clinician interactions. This real-time information helps patients report pain relief in significantly less time than with traditional programming¹. HFX AdaptivAI gives physicians the ability to remotely monitor each of their patient’s pain journeys in real time through Nevro’s healthcare provider portal.
 
“HFX AdaptivAI is a significant leap forward in pain management,” said Dr. Usman Latif, MD, MBA, a Harvard-trained interventional pain specialist at The University of Kansas Health System. “Drawing from landmark evidence and big data, this technology has the potential to offer patients a faster and more sustainable approach to pain relief. HFX AdaptivAI is on the right path to make a lasting impact on how we manage chronic pain and improve patient outcomes.”
 
“Chronic pain is a dynamic, biopsychosocial human condition unique to each individual³,” said Dr. David Caraway, MD, PhD, Nevro’s chief medical officer. “To effectively treat suffering – as perceived by each patient – therapies must be personalized based on the changing experience of pain. Only HFX AdaptivAI seeks to engage with the patient and personalize the SCS therapy in real time using evidence based on algorithms and multi-dimensional metrics of pain relief, function, and satisfaction.”
 
Nevro is also preparing for a full market release of HFX iQ with HFX AdaptivAI in the U.S. in the fourth quarter of 2024.
 

References:

**HFX AdaptivAI™ customized programs are pre-defined parameters programmed by the physician.
¹ Data on file.
² Data on file, 3% PD 10 KHz 30 μs 2.0 mA 20 secs 10mins 800 Ohms.
3 Deer T.R., Caraway D.L., Wallace M.S. 2014. A Definition of Refractory Pain to Help Determine Suitability for Device Implantation. Neuromodulation 2014; 17: 711–715